Ascendis Pharma A/S (ASND)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in EUR.

Revenue TTM

0 250M 500M 750M Q1 '24: 329M Q2 '24: 317.6M Q3 '24: 327.4M Q4 '24: 363.6M Q1 '25: 368.7M Q2 '25: 490.7M Q3 '25: 646.5M Q4 '25: 720.1M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Gross Profit TTM

0 250M 500M 750M Q1 '24: 281.7M Q2 '24: 271.7M Q3 '24: 277.7M Q4 '24: 319.4M Q1 '25: 314.5M Q2 '25: 416.6M Q3 '25: 561.2M Q4 '25: 625.2M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q1 '24: -361M Q2 '24: -353.4M Q3 '24: -315.8M Q4 '24: -278.8M Q1 '25: -333.8M Q2 '25: -253.5M Q3 '25: -145.8M Q4 '25: -136.3M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q1 '24: -501.6M Q2 '24: -489.5M Q3 '24: -426.5M Q4 '24: -378.1M Q1 '25: -341.7M Q2 '25: -271.1M Q3 '25: -232.9M Q4 '25: -228M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Cost of Revenue TTM

0 35M 70M 105M Q1 '24: 47.3M Q2 '24: 45.9M Q3 '24: 49.7M Q4 '24: 44.3M Q1 '25: 54.2M Q2 '25: 74.2M Q3 '25: 85.3M Q4 '25: 94.9M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q1 '24: -421.9M Q2 '24: -330.1M Q3 '24: -261.5M Q4 '24: -306.2M Q1 '25: -218.9M Q2 '25: -165M Q3 '25: -106.7M Q4 '25: 53.9M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Free Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q4 '22: -510.2M Q1 '23: -523.7M Q2 '23: -549.2M Q3 '23: -572.9M Q4 '23: -469.8M Q1 '24: -423.5M Q2 '24: -331.5M Q3 '24: -262.4M Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '23: 56.2M Q3 '23: 56.3M Q1 '24: 56.9M Q2 '24: 60.8M Q3 '24: 57.5M Q1 '25: 60M Q2 '25: 63.9M Q3 '25: 60.8M Q2 '23 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q1 '24: -8.87 Q2 '24: -8.62 Q3 '24: -7.46 Q4 '24: -6.53 Q1 '25: -5.81 Q2 '25: -4.54 Q3 '25: -3.82 Q4 '25: -3.76 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.